Synapse - Surgery

Results (100)

Event-free survival (EFS) and patient-reported outcomes (PROs) in MATTERHORN: A randomised, phase III study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) chemotherapy in resectable gastric/ gastroesophageal junction (G/GEJ) adenocarcinoma

Meeting Abstract

Al-Batran, S. E.; Wainberg, Z. A.; Muro, K.; Molena, D.; Van Cutsem, E.; Hyung, W. J.; Wyrwicz, L. S.; Moehler, M.; Herrero, F. R.; Oh, D. Y.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Comments on the study of lung cancer detection by electronic nose analysis of exhaled breath

Correspondence

Rocco, G.
Annals of Oncology (2025)

Fulltext@MSK | Save

Oncologic outcomes of retroperitoneal lymph node dissection following first-line chemotherapy for metastatic non-seminomatous germ-cell tumors

Journal Article

Matulewicz, R. S.; Baky, F.; Liso, N.; Williams, B. M.; Porwal, S.; Assel, M.; Carver, B. S.; Bajorin, D. F.; Motzer, R. J.; Bosl, G. J.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Reply to the letter to the editor by Perez et al. regarding “survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: A pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials”

Correspondence

Garcia-Aguilar, J.; Williams, H.; Fokas, E.; Rodel, C.
Annals of Oncology (2025)

Fulltext@MSK | Save

Survival among patients treated with total mesorectal excision or selective watch-and-wait after total neoadjuvant therapy: A pooled analysis of the CAO/ARO/AIO-12 and OPRA randomized phase II trials

Journal Article

Williams, H.; Fokas, E.; Diefenhardt, M.; Lee, C.; Verheij, F. S.; Omer, D. M.; Lin, S. T.; Dunne, R. F.; Marcet, J.; Cataldo, P.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Tumor and blood B-cell abundance outperforms established immune checkpoint blockade response prediction signatures in head and neck cancer

Journal Article

Chang, T. G.; Spathis, A.; Schäffer, A. A.; Gavrielatou, N.; Kuo, F.; Jia, D.; Mukherjee, S.; Sievers, C.; Economopoulou, P.; Anastasiou, M.; more...
Annals of Oncology (2025)

Fulltext@MSK | Save

Reply to the letter to the editor ‘circulating tumor DNA after definitive therapy for locally advanced rectal cancer’ by Drs Sorscher and Rocha Lima

Correspondence

Bercz, A.; Smith, J. J.; Romesser, P. B.
Annals of Oncology (2025)

Fulltext@MSK | Save

Peripheral blood (PB) T cell phenotype and tumor microenvironment (TME) subtype are independently associated with immune checkpoint blockade (ICB) outcomes in sarcomas

Meeting Abstract

Rosenbaum, E.; Ehrich, F.; Bradic, M.; Kelly, C. M.; Movva, S.; Chan, J.; Chi, P.; Banks, L.; Dickson, M.; Keohan, M. L.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)

Meeting Abstract

Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save

An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)

Meeting Abstract

Bartlett, E. K.; Li, D.; Shemla, S.; Ariyan, C. E.; Dickinson, S.; Crago, A.; Li, G.; Agaram, N.; D'Angelo, S. P.; Maki, R. G.; more...
Annals of Oncology (2024)

Fulltext@MSK | Save